EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENT May 16, 2011Executive Change of Control and Severance Agreement • February 17th, 2012 • Fei Co • Laboratory analytical instruments • Oregon
FEI considers the establishment and maintenance of a sound and vital management to be essential to protecting and enhancing the best interests of FEI and its shareholders. FEI recognizes that, as is the case with many publicly held corporations, the possibility of a change of control may exist and that such possibility, and the uncertainty and questions which it may raise among management, may result in the departure or distraction of management personnel to the detriment of FEI and its shareholders. In order to induce Executive to remain employed by FEI in the face of uncertainties about the long-term strategies of FEI and possible change of control of FEI and their potential impact on Executive's position with FEI, this Executive Change of Control and Severance Agreement (“Agreement”), which has been approved by the Board of Directors of FEI, sets forth the severance benefits that FEI will provide to Executive in the event Executive's employment by FEI is terminated under the circums
EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENTExecutive Change of Control and Severance Agreement • August 8th, 2007 • Adams Golf Inc • Sporting & athletic goods, nec • Texas
THIS AGREEMENT (the "Agreement") is made and entered into as of this 15th day of May, 2007 by and between Adams Golf Management Corp, a Delaware corporation, and the corporation's Chief Financial Officer , Eric Logan (the "Executive"). Adams Golf Management Corp. is sometimes referred to herein as the "Employer".
EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENT (this “Agreement”)Executive Change of Control and Severance Agreement • June 21st, 2013 • TearLab Corp • Surgical & medical instruments & apparatus • California
WHEREAS the Executive is currently employed with the Corporation in an executive capacity and has extensive access to the customers, suppliers, distribution processes and other unique and valuable confidential information and trade secrets of the Corporation;
EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENT (this “Agreement”)Executive Change of Control and Severance Agreement • June 21st, 2013 • TearLab Corp • Surgical & medical instruments & apparatus • Ontario
WHEREAS the Executive is currently employed with the Corporation in an executive capacity and has extensive access to the customers, suppliers, distribution processes and other unique and valuable confidential information and trade secrets of the Corporation;
EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENTExecutive Change of Control and Severance Agreement • March 3rd, 2015 • Fei Co • Laboratory analytical instruments • Oregon
FEI considers the establishment and maintenance of a sound and vital management to be essential to protecting and enhancing the best interests of FEI and its shareholders. FEI recognizes that, as is the case with many publicly held corporations, the possibility of a change of control may exist and that such possibility, and the uncertainty and questions which it may raise among management, may result in the departure or distraction of management personnel to the detriment of FEI and its shareholders. In order to induce Executive to remain employed by FEI in the face of uncertainties about the long-term strategies of FEI and possible change of control of FEI and their potential impact on Executive’s position with FEI, this Executive Change of Control and Severance Agreement (“Agreement”), which has been approved by the Board of Directors of FEI, sets forth the severance benefits that FEI will provide to Executive in the event Executive’s employment by FEI is terminated under the circums
HYPERION THERAPEUTICS, INC. EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENTExecutive Change of Control and Severance Agreement • April 13th, 2012 • Hyperion Therapeutics Inc • California
This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between (the “Executive”) and Hyperion Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
